Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Laura Goodall"'
Autor:
Daniel Rycroft, Jane Sosabowski, Edward Coulstock, Marie Davies, John Morrey, Sarah Friel, Fiona Kelly, Robert Hamatake, Milan Ovečka, Rob Prince, Laura Goodall, Armin Sepp, Adam Walker
Publikováno v:
PLoS ONE, Vol 10, Iss 2, p e0117847 (2015)
Interferon alpha (IFNα) is used for the treatment of hepatitis B virus infection, and whilst efficacious, it is associated with multiple adverse events caused by systemic exposure to interferon. We therefore hypothesise that targeting IFN directly t
Externí odkaz:
https://doaj.org/article/56fd44d4bac24be0a642cc7183554b60
Autor:
Edward Coulstock, Jane Sosabowski, Milan Ovečka, Rob Prince, Laura Goodall, Clare Mudd, Armin Sepp, Marie Davies, Julie Foster, Jerome Burnet, Gráinne Dunlevy, Adam Walker
Publikováno v:
PLoS ONE, Vol 8, Iss 2, p e57263 (2013)
Interferon alpha (IFNα) is used for the treatment of hepatitis C infection and whilst efficacious it is associated with multiple adverse events including reduced leukocyte, erythrocyte, and platelet counts, fatigue, and depression. These events are
Externí odkaz:
https://doaj.org/article/2bf102b9d60e482eb3241a465d3d6f8f
Autor:
Andrew Sanderson, A. Allart Stoop, Daniel Rycroft, Marie Davies, Laura Goodall, Milan Ovečka, Prafull Mistry, Sarah Friel
Publikováno v:
PLoS ONE, Vol 10, Iss 9, p e0137065 (2015)
PLoS ONE
PLoS ONE
Tumour Necrosis Factor-α (TNF-α) inhibition has been transformational in the treatment of patients with inflammatory disease, e.g. rheumatoid arthritis. Intriguingly, TNF-α signals through two receptors, TNFR1 and TNFR2, which have been associated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a673a156157c878e484b589169b78b83
http://europepmc.org/articles/PMC4564187?pdf=render
http://europepmc.org/articles/PMC4564187?pdf=render
Autor:
Fiona M. Kelly, Robert Hamatake, Daniel Rycroft, Rob Prince, Edward Coulstock, Marie Davies, Milan Ovečka, John D. Morrey, Sarah Friel, Adam Walker, Laura Goodall, Jane K. Sosabowski, Armin Sepp
Publikováno v:
PLoS ONE
PLoS ONE, Vol 10, Iss 2, p e0117847 (2015)
PLoS ONE, Vol 10, Iss 2, p e0117847 (2015)
Interferon alpha (IFNα) is used for the treatment of hepatitis B virus infection, and whilst efficacious, it is associated with multiple adverse events caused by systemic exposure to interferon. We therefore hypothesise that targeting IFN directly t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eaa9670c6cefeb91d6476677062776f0
https://pubmed.ncbi.nlm.nih.gov/25860813
https://pubmed.ncbi.nlm.nih.gov/25860813